A Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine With and Without Adjuvant in Healthy Older Adults
Open Access
- 11 May 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 226 (12), 2054-2063
- https://doi.org/10.1093/infdis/jiac189
Abstract
Respiratory syncytial virus (RSV) is an important cause of disease in older adults. We evaluated the safety and immunogenicity of a stabilized RSV prefusion F subunit (RSVpreF) vaccine candidate with/without adjuvant in adults aged 65–85 years. Primary cohort participants were equally randomized to 1 of 7 RSVpreF formulations: 60 µg with either Al(OH)3 or CpG/Al(OH)3, 120 µg with either Al(OH)3 or CpG/Al(OH)3, 240 µg with either Al(OH)3 or CpG/Al(OH)3, 240 µg unadjuvanted, or placebo, administered concomitantly with high-dose seasonal inactivated influenza vaccine (SIIV). Participants in the month 0,2 cohort were randomized to RSVpreF 240 µg with CpG/Al(OH)3 or placebo, administered at months 0 and 2. All RSVpreF vaccine candidates elicited robust and persistent serum neutralizing responses when administered alone or with SIIV. There was no notable difference in neutralizing response between the formulations, including those containing CpG. In the month 0,2 cohort, there was no booster effect of dose 2. SIIV responses were similar or slightly lower with concomitant administration of RSVpreF. Most systemic and local reactions were mild and more frequent after RSVpreF than placebo. RSVpreF formulations were well tolerated and elicited robust neutralizing responses in older adults; however, CpG/Al(OH)3 did not further enhance responses. Clinical Trials Registration. NCT03572062.Keywords
Funding Information
- Pfizer Inc.
This publication has 16 references indexed in Scilit:
- Recommendations of the Advisory Committee on Immunization Practices for Use of a Hepatitis B Vaccine with a Novel AdjuvantMorbidity and Mortality Weekly Report (MMWR), 2018
- An Adjuvanted, Postfusion F Protein–Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older AdultsThe Journal of Infectious Diseases, 2017
- Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta-analysisVaccine, 2016
- Immunosenescence and vaccine failure in the elderly: Strategies for improving responseImmunology Letters, 2014
- Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjectsVaccine, 2014
- Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancerVaccine, 2014
- Medically Attended Respiratory Syncytial Virus Infections in Adults Aged >=50 Years: Clinical Characteristics and OutcomesClinical Infectious Diseases, 2013
- Respiratory Syncytial Virus–Associated Hospitalizations Among Children Less Than 24 Months of AgePEDIATRICS, 2013
- Respiratory Syncytial Virus Infection in Elderly and High-Risk AdultsThe New England Journal of Medicine, 2005
- Risk Factors for Severe Respiratory Syncytial Virus Infection in Elderly PersonsThe Journal of Infectious Diseases, 2004